Translational Research in Maternal and Pediatric Pharmacology and Therapeutics

USA's National Institutes of Health (NIH) is inviting applications for Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional). Deadline: 10 December, 2020.

Purpose

The purpose of this funding opportunity announcement (FOA) is to encourage applications that will perform basic, translational and clinical research to

(1) advance the understanding of underlying mechanisms of drug action;

(2) discover and develop novel therapeutics;

(3) enhance the usage of existing drugs or drug repurposing for safer and more effective treatment for pregnant women, lactating women, neonates and children.

The overall goal is to improve drug safety and efficacy for maternal and pediatric precision therapeutics.

Eligibility:

Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, are allowed. 

Further information and application process

For detailed information on the opportunity, budget and how to apply, please visit the NiH website

Published Oct. 2, 2020 1:57 PM - Last modified Oct. 2, 2020 1:57 PM